Oppenheimer & Co. Inc. Has $795,000 Stock Holdings in Teladoc Health, Inc. (NYSE:TDOC)

Oppenheimer & Co. Inc. lifted its stake in shares of Teladoc Health, Inc. (NYSE:TDOC) by 137.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 86,551 shares of the health services provider’s stock after purchasing an additional 50,026 shares during the quarter. Oppenheimer & Co. Inc. owned about 0.05% of Teladoc Health worth $795,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in TDOC. State Board of Administration of Florida Retirement System lifted its holdings in shares of Teladoc Health by 2.2% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 173,878 shares of the health services provider’s stock worth $2,626,000 after purchasing an additional 3,777 shares in the last quarter. Mitsubishi UFJ Trust & Banking Corp grew its holdings in shares of Teladoc Health by 140.4% during the first quarter. Mitsubishi UFJ Trust & Banking Corp now owns 53,682 shares of the health services provider’s stock valued at $797,000 after buying an additional 31,355 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Teladoc Health in the 1st quarter worth about $100,000. Covestor Ltd boosted its stake in Teladoc Health by 58.1% during the 1st quarter. Covestor Ltd now owns 3,817 shares of the health services provider’s stock valued at $57,000 after purchasing an additional 1,403 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of Teladoc Health in the first quarter worth approximately $300,000. 76.82% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Teladoc Health

In other news, Director Thomas Mckinley purchased 4,000 shares of Teladoc Health stock in a transaction that occurred on Thursday, September 12th. The shares were bought at an average cost of $7.69 per share, with a total value of $30,760.00. Following the completion of the purchase, the director now directly owns 39,077 shares in the company, valued at approximately $300,502.13. This trade represents a 11.40 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Mala Murthy sold 8,750 shares of the business’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.16, for a total transaction of $62,650.00. Following the sale, the chief financial officer now owns 85,767 shares in the company, valued at approximately $614,091.72. This trade represents a 9.26 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 20,051 shares of company stock worth $143,565 over the last quarter. Corporate insiders own 0.95% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Stifel Nicolaus decreased their price target on Teladoc Health from $16.00 to $9.00 and set a “hold” rating for the company in a report on Thursday, August 1st. Evercore ISI increased their target price on shares of Teladoc Health from $8.00 to $9.00 and gave the company an “in-line” rating in a report on Tuesday, October 8th. DA Davidson cut their price target on shares of Teladoc Health from $12.00 to $8.00 and set a “neutral” rating on the stock in a report on Thursday, August 1st. Barclays increased their price objective on shares of Teladoc Health from $10.00 to $12.00 and gave the company an “overweight” rating in a research note on Thursday, October 31st. Finally, The Goldman Sachs Group assumed coverage on Teladoc Health in a report on Friday, November 15th. They issued a “buy” rating and a $14.00 target price for the company. Fourteen research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $12.08.

Teladoc Health Trading Down 1.3 %

Shares of TDOC opened at $8.93 on Wednesday. The stock has a market capitalization of $1.54 billion, a P/E ratio of -1.55 and a beta of 0.90. Teladoc Health, Inc. has a twelve month low of $6.76 and a twelve month high of $22.54. The company has a quick ratio of 1.69, a current ratio of 1.73 and a debt-to-equity ratio of 0.66. The firm has a fifty day simple moving average of $8.96 and a two-hundred day simple moving average of $9.31.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings data on Wednesday, October 30th. The health services provider reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.10. Teladoc Health had a negative return on equity of 10.06% and a negative net margin of 37.91%. The business had revenue of $640.51 million during the quarter, compared to analysts’ expectations of $630.50 million. On average, research analysts anticipate that Teladoc Health, Inc. will post -1.17 EPS for the current year.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.